Physician profile
Robert H Bleicher
NPI 1467442426
$8,874.02
in general payments reported to CMS, 2019-2025
34 companies · $1,373 in 2025
The $1,373 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $989 · 2020: $716 · 2021: $1,225 · 2022: $1,652 · 2023: $1,386 · 2024: $1,533 · 2025: $1,373.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,293.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,292.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,069.76 | 2019-2025 | Rinvoq, Skyrizi, Creon |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,528.20 | 2019-2025 | Trulance, Xifaxan, Plenvu |
| Janssen Biotech, INC. | $931.09 | 2019-2025 | Stelara, Tremfya, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $563.59 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Celgene Corporation | $547.37 | 2021-2024 | Zeposia |
| Pfizer INC. | $417.95 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $407.21 | 2019-2024 | Dificid, Zinplava |
| Intercept Pharmaceuticals, INC. | $260.41 | 2019-2025 | |
| Aimmune Therapeutics, INC. | $258.16 | 2024-2025 | Zenpep |
| Ardelyx, INC. | $253.65 | 2022-2025 | Ibsrela |
| E.R. Squibb & Sons, L.L.C. | $247.27 | 2022-2023 | |
| Phathom Pharmaceuticals, INC. | $233.88 | 2024-2025 | Voquezna |
| Ironwood Pharmaceuticals, INC | $186.40 | 2019-2023 | Linzess |
| Ferring Pharmaceuticals INC. | $173.31 | 2019-2024 | Rebyota |
| Braintree Laboratories, INC. | $116.36 | 2019-2025 | Sutab, Suflave |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $78.49 | 2024-2025 | Rezdiffra, Resmetirom |
| Qol Medical, LLC | $65.65 | 2022-2024 | Sucraid |
| Celltrion USA INC. | $55.19 | 2025 | Vegzelma |
| Laborie Medical Technologies Corp. | $51.75 | 2024 | |
| Ucb, INC. | $43.25 | 2019 | |
| Redhill Biopharma INC. | $43.04 | 2021-2023 | |
| Nestle Healthcare Nutrition INC. | $40.07 | 2022-2023 | |
| Biocon Biologics INC | $38.94 | 2025 | Yesintek |
| Novo Nordisk INC | $36.94 | 2025 | Wegovy |
| Ipsen Biopharmaceuticals, INC | $35.98 | 2024-2025 | Iqirvo, Bylvay |
| Cumberland Pharmaceuticals, INC. | $29.70 | 2022-2023 | Kristalose |
| Gilead Sciences, INC. | $29.36 | 2021 | |
| Organon LLC | $28.86 | 2021 | |
| Allergan, INC. | $25.24 | 2019 | |
| W. L. Gore & Associates, INC. | $19.17 | 2022 | |
| Genzyme Corporation | $15.56 | 2022 | |
| Blueprint Medicines Corporation | $15.34 | 2024 | Ayvakit |
| Lilly USA, LLC | $14.52 | 2025 | Omvoh |
| Alfasigma USA, INC. | $12.36 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Bleicher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.